Invention Grant
- Patent Title: Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer
-
Application No.: US17411265Application Date: 2021-08-25
-
Publication No.: US11807853B2Publication Date: 2023-11-07
- Inventor: Mariano A. Garcia-Blanco , Gaddiel Galarza-Munoz , Shelton S. Bradrick
- Applicant: Board of Regents, The University of Texas System
- Applicant Address: US TX Austin
- Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
- Current Assignee Address: US TX Austin
- Agency: Chalker Flores, LLP
- Agent Edwin S. Flores; Daniel J. Chalker
- Main IPC: C12N15/113
- IPC: C12N15/113 ; A61K31/7088 ; A61K45/06 ; C12Q1/68

Abstract:
The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).
Public/Granted literature
- US20210403920A1 SOLUBLE INTERLEUKIN-7 RECEPTOR (SIL7R) MODULATING THERAPY TO TREAT AUTOIMMUNE DISEASES AND CANCER Public/Granted day:2021-12-30
Information query
IPC分类: